Compare KMT & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KMT | SLBT |
|---|---|---|
| Founded | 1938 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | 20 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 1994 | N/A |
| Metric | KMT | SLBT |
|---|---|---|
| Price | $33.91 | $4.11 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $36.00 | N/A |
| AVG Volume (30 Days) | ★ 997.2K | 236.9K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $1,966,845,000.00 | N/A |
| Revenue This Year | $14.24 | N/A |
| Revenue Next Year | $7.57 | N/A |
| P/E Ratio | $22.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.62 | $3.23 |
| 52 Week High | $43.81 | $6.25 |
| Indicator | KMT | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 46.21 |
| Support Level | $33.85 | $3.63 |
| Resistance Level | $35.10 | $4.91 |
| Average True Range (ATR) | 1.16 | 0.73 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 47.52 | 26.08 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.